Publicacións en colaboración con investigadores/as de Hospital Arnau de Vilanova (36)

2025

  1. Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction

    The New England journal of medicine, Vol. 393, Núm. 19, pp. 1889-1900

  2. Predictors of Survival in Metastatic Malignant Pleural Effusions: The GASENT Score

    Archivos de Bronconeumologia, Vol. 61, Núm. 11, pp. 680-689

2023

  1. Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus

    Acta Dermato-Venereologica, Vol. 103

  2. “Long-term oncologic outcomes and risk factors for distant recurrence after pathologic complete response following neoadjuvant treatment for locally advanced rectal cancer. A nationwide, multicentre study”

    European Journal of Surgical Oncology, Vol. 49, Núm. 10

2022

  1. Differences Between Takotsubo and the Working Diagnosis of Myocardial Infarction With Nonobstructive Coronary Arteries

    Frontiers in Cardiovascular Medicine, Vol. 9

2021

  1. A 3-Biomarker 2-Point-Based Risk Stratification Strategy in Acute Heart Failure

    Frontiers in Physiology, Vol. 12

  2. Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)

    Leukemia Research, Vol. 109

  3. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

    Blood, Vol. 137, Núm. 14, pp. 1879-1894

  4. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020

    Nature, Vol. 595, Núm. 7869, pp. 707-712

  5. The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant

    Nature Genetics, Vol. 53, Núm. 10, pp. 1405-1414

2020

  1. A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial

    Cancer Medicine, Vol. 9, Núm. 7, pp. 2317-2329

  2. Prevalence, clinical profile and prognostic implications of interatrial block in patients admitted for heart failure

    REC: CardioClinics, Vol. 55, Núm. 3, pp. 155-164

  3. Reducing residual thrombotic risk in patients with peripheral artery disease: Impact of the COMPASS trial

    Drugs in Context, Vol. 9

  4. Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition

    Expert Review of Clinical Pharmacology, Vol. 13, Núm. 7, pp. 695-706

  5. Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, Núm. 8, pp. e513-e522

  6. Two vs. three weeks of treatment with amoxicillin-clavulanate for stabilized community-acquired complicated parapneumonic effusions. A preliminary non-inferiority, double-blind, randomized, controlled trial

    Pleura and Peritoneum, Vol. 5, Núm. 1

  7. Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia

    Haematologica

2019

  1. Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group

    Cancer, Vol. 125, Núm. 16, pp. 2810-2817

2018

  1. Development and validation of a scoring system for the identification of pleural exudates of cardiac origin

    European Journal of Internal Medicine, Vol. 50, pp. 60-64

  2. Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain

    Diabetic Medicine, Vol. 35, Núm. 11, pp. 1605-1612